t-2307 and Malaria

t-2307 has been researched along with Malaria* in 1 studies

Other Studies

1 other study(ies) available for t-2307 and Malaria

Article	Year
In vitro and in vivo antimalarial activities of T-2307, a novel arylamidine. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:4 T-2307, a novel arylamidine, has been shown to exhibit broad-spectrum antifungal activities against clinically significant pathogens. Here, we evaluated the in vitro and in vivo antimalarial activity of T-2307. The 50% inhibitory concentrations (IC₅₀s) of T-2307 against Plasmodium falciparum FCR-3 and K-1 strains were 0.47 and 0.17 μM, respectively. T-2307 at 2.5 to 10 mg/kg of body weight/day exhibited activity against blood stage and liver stage parasites in rodent malaria models. In conclusion, T-2307 exhibited in vitro and in vivo antimalarial activity. Topics: Amidines; Animals; Antimalarials; Humans; Inhibitory Concentration 50; Liver; Malaria; Male; Mice; Mice, Inbred BALB C; Parasite Load; Plasmodium berghei; Plasmodium chabaudi; Plasmodium falciparum	2012

Article

Year

In vitro and in vivo antimalarial activities of T-2307, a novel arylamidine.

Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:4

T-2307, a novel arylamidine, has been shown to exhibit broad-spectrum antifungal activities against clinically significant pathogens. Here, we evaluated the in vitro and in vivo antimalarial activity of T-2307. The 50% inhibitory concentrations (IC₅₀s) of T-2307 against Plasmodium falciparum FCR-3 and K-1 strains were 0.47 and 0.17 μM, respectively. T-2307 at 2.5 to 10 mg/kg of body weight/day exhibited activity against blood stage and liver stage parasites in rodent malaria models. In conclusion, T-2307 exhibited in vitro and in vivo antimalarial activity.

Topics: Amidines; Animals; Antimalarials; Humans; Inhibitory Concentration 50; Liver; Malaria; Male; Mice; Mice, Inbred BALB C; Parasite Load; Plasmodium berghei; Plasmodium chabaudi; Plasmodium falciparum

2012